



In the name of GOD

101001010100111101000010010111010010 1101010101011101000041000101010100
004100001010010100100101000010101001010140000111101001010100111101000010010111010010
110101010101110100004100001010010100100101000010110100101014000011110100101

A microscopic view of several red blood cells, showing their characteristic biconcave disc shape. The cells are arranged in a cluster, with one cell in the foreground being larger and more prominent than the others. The background is a light, slightly blurred pinkish-red color.


Hemolytic Anemia

Dr. Shiva Nazari


*Assistant Professor of Pediatric Oncologist & Hematologist
Shahid Beheshti Medical Science University
Mofid Children's Hospital*

Reduction in the normal red cell survival (120 days)

Reticuloendothelial cell



Hemoglobin Catabolism



Intervascular Hemoglobin Catabolism



Destruction

A. Corpuscular abnormalities

- Cell membrane abnormalities
- Enzymes abnormalities
- Hemoglobin abnormalities

B. Extracorpuseular abnormalities

- Immune mechanisms
- Non immune mechanisms

Approach to diagnosis

- 1. Consideration of clinical feature suggesting hemolytic disease**
- 2. Laboratory demonstration of presence of hemolytic process**
- 3. Determination of the cause of hemolytic anemia**



Clinical Features

Suggest a hemolytic process:

- 1. Ethnic factors**
- 2. Age factors**
- 3. History of anemia, Jaundice, gall stone in family**
- 4. Persistent anemia associated with reticytosis**
- 5. Anemia unresponsive to hematinics**
- 6. Splenomegaly**
- 7. Hemoglobinuria**
- 8. Dark urine**



Laboratory Findings

- **Reduce red cell and evidence accelerated of hemoglobin catabolism**
- **Evidence of increased erythropiesis**

Signs of Extravascular Hemolysis:

- 1) Increased unconjugated bilirubin**
- 2) Increased fecal urinary urobilinogen**

Signs of Intravascular Hemolysis:

- 1) Raised plasma hemoglobin
- 2) Hemoglobinuria
- 3) Hemosiderinuria
- 4) Haptoglobin low

Increased Erythropoiesis

- 1) Reticulocytosis**
- 2) MCV increased**
- 3) RDW increased**
- 4) Increased normoblasts**
- 5) Specific morphologic abnormalities**
 - Sickle cells – Target cells
 - Basophil stippling – Spherocyt
- 6) *Expansion of marrow space in chronic hemolysis***
 - Prominence of frontal bones*
 - Hair – on – end appearance of skull*
 - Biconcave vertebrae (Fish – mouth)*
- 7) *Decreased red cell survival (Cr 51)***

Test Used to Demonstrate Hemolytic Anemia

- 1) Hemoglobine , Hematocrit , RBC count ↓
- 2) Serum hepatoglubin ↓
- 3) RBC survival (Cr ⁵¹) ↓
- 4) LDH (Isoenzymes)
- 5) Bilirubin level ↑
- 6) Hemoglobinuria ↑
- 7) Reticulocyts ↑
- 8) Antiglobin test (Coomb's test) + - ↑

Test Used to Establish

Specific Cause of Hemolytic Anemia

A - RBC defect :

- 1) Membrane :
 - Osmotic fragility
 - Blood Smear
 - Autohemolysis
- 2) Hemoglobin :
 - Sickling test
 - Hemoglobin electrophoresis
(Fetal hemoglobin)
- 3) Enzyme :
 - Heinz - body
 - G6PD , PK (**Specific enzym assay**)

B - Aquired hemolytic :

- Coomb's test
- Antibody screening
- Blood group - Rh



Hereditary spherocytosis

Genetics :

- **Autosomal dominant**
- **Family history in 75 %**
- **Incidence 1/5000**

Pathogenesis

- 1- Dysfunction of RBC skeletal protein**
- 2- Extravascular hemolysis (spleen)**
- 3- Decreased surface -area -volume -ratio**
- 4- Tendency to spherocytosis (reduce flexibility)**
- 5- Cell dehydration**

Test hematology

Hemoglobine , Hematocrit , RBC count

MCV decreased

**MCHC increased
(3-15%)**

Osmotic fragility test

Autohemolysis increased (correct by glucose)

Retic



Clinical features

Anemia

Jaundice (depend on rate hemolysis)

Splenomegaly

Newborn hyperbilirubinemia

Gallstones

Treatment

Folic acid supplement (1mg/day)

Packed red cell transfusion

Splenectomy after 5 year



Glucose 6-Phosphate Dehydrogenase deficiency(G6PD)

G6PD → *Pentose Phosphate Pathway*

1- Sex linked (X - Chromosome)

2- Variable intermediate expression (Female)

(lyon hypotesis – Random deletion X)

3- 35% - In mediterranean

WHO Classification

Class I Chronic hemolytic anemia

Class II Intermittent hemolysis (mediterranean)

Class III -Intermittent hemolysis (infection- drug)

Patogenesis

- 1 – Red cell G-6PD activity fall was RBC age
- 2- ↓ glucose metabolism
- 3- ↓ NADPH / NADP
- 4 - ↑ H₂O₂
- 5 - Oxidation hemoglubin



Clinical features

Episodes of hemolysis may be produced by:

- **Drugs**
- **Fava bean**
- **Infection**



- 1- Acute self limiting hemolytic anemia
- 2- Hemoglobinuria
- 3- Heinz bodies
- 4- Blister cell ,spherocyt
- 5- Reticulocytosis
- 6- Hemoglobin normal between episodes
- 7- Blood transfusion required
- 8 - Acute renal failure
- 9 - Neonatal jaundice
- 10- Chronic hemolysis (European)
 - Increased autohemolysis (Not correct)
 - Splenomegaly



Treatment

1 – Avoidance

2 – Transfusion packed red blood

- Hb 7 g / dL
- Persistent hemoglobinuria Hb 9 g / dL

Classification of Immune hemolytic anemia

A – Autoimmune


- Associated with warm antibodies (IgG)
- Associated with cold antibodies (IgM)

B – Isoimmune

- Hemolytic disease of the newborn
- Rh & ABO incompatibility

C - Drug induced

- Immune complexes to RBC membrane
- Adsorption of drug to RBC
- Autoantibody to drug (Insulin , antihistamine , Sulphanamid)





Any Questions?

Thank you